Dapagliflozin and Empagliflozin in Paediatric Indications: A Systematic Review
ConclusionEarly evidence suggests that dapagliflozin and empagliflozin are well tolerated in children. A clinical pharmacology rationale currently exists only for adolescents with diabetes mellitus.Prospero Registration NumberCRD42023438162. (Source: Pediatric Drugs)
Source: Pediatric Drugs - April 18, 2024 Category: Pediatrics Source Type: research
Population Pharmacokinetics of Adalimumab in Juvenile Idiopathic Arthritis Patients: A Retrospective Cohort Study Using Clinical Care Data
ConclusionsFive literature models effectively described adalimumab PK in this pediatric cohort, highlighting the potential for extrapolating existing models to the pediatric population. The new JIA model confirmed the effect of several known covariates and found a novel association for drug clearance with methotrexate use (lower) and uveitis (higher), which might have clinical relevance for personalized dosing in JIA. (Source: Pediatric Drugs)
Source: Pediatric Drugs - April 17, 2024 Category: Pediatrics Source Type: research
Distribution of Bevacizumab into the Cerebrospinal Fluid of Children and Adolescents with Recurrent Brain Tumors
ConclusionsThis pharmacokinetic pilot study indicated penetration of bevacizumab into the CSF in a population of children, adolescents, and young adults with recurrent brain tumors. (Source: Pediatric Drugs)
Source: Pediatric Drugs - April 8, 2024 Category: Pediatrics Source Type: research
Neonatal Necrotizing Enterocolitis: An Update on Pathophysiology, Treatment, and Prevention
AbstractNecrotizing enterocolitis (NEC) is a life-threatening disease predominantly affecting premature and very low birth weight infants resulting in inflammation and necrosis of the small bowel and colon and potentially leading to sepsis, peritonitis, perforation, and death. Numerous research efforts have been made to better understand, treat, and prevent NEC. This review explores a variety of factors involved in the pathogenesis of NEC (prematurity, low birth weight, lack of human breast milk exposure, alterations to the microbiota, maternal and environmental factors, and intestinal ischemia) and reports treatment modal...
Source: Pediatric Drugs - April 2, 2024 Category: Pediatrics Source Type: research
Comparison of Deep and Moderate Neuromuscular Blockade for Major Laparoscopic Surgery in Children: A Randomized Controlled Trial
ConclusionsA deep NMB provided better operative conditions and similar recovery profiles compared with a moderate NMB as reversed with sugammadex in children undergoing major laparoscopic surgery.Clinical Trial RegistrationChinese Clinical Trial Registry, No. ChiCTR2100053821. (Source: Pediatric Drugs)
Source: Pediatric Drugs - March 21, 2024 Category: Pediatrics Source Type: research
The Effect of Polymorphisms and Other Biomarkers on Infliximab Exposure in Paediatric Inflammatory Bowel Disease: Development of a Population Pharmacokinetic Model
ConclusionsA popPK model utilising weight, albumin, FC, ESR, and the SNP rs1048610 accurately predicted infliximab trough concentrations in children with IBD. (Source: Pediatric Drugs)
Source: Pediatric Drugs - March 20, 2024 Category: Pediatrics Source Type: research
Treatment Options for Alopecia Areata in Children and Adolescents
AbstractAlopecia areata (AA) lifetime incidence is around 2%, with many patients first experiencing symptoms during childhood. However, ritlecitinib is the only FDA-approved treatment for pediatric patients 12 years and older. This review outlines reported topical, injectable, and oral treatment options for pediatric patients with AA. Clinical studies were obtained via a PubMed search using the following search terms: alopecia areata, areata, universalis, or totalis and medication, therapy, treatment, drug, or management. Only studies with pediatric patients were included in this review. Commonly used therapies, including ...
Source: Pediatric Drugs - March 11, 2024 Category: Pediatrics Source Type: research
Practical Approach to Diagnosis and Management of IL-1-Mediated Autoinflammatory Diseases (CAPS, TRAPS, MKD, and DIRA)
AbstractSystemic autoinflammatory diseases (SAIDs) are a group of rare genetic and nongenetic immune dysregulatory disorders associated with high morbidity and mortality if left untreated. Therefore, early diagnosis and initiation of targeted treatment is vital in SAID patients to control the disease activity and prevent long-term immune-mediated damage. A specific group of genetically defined SAIDs is associated with increased inflammasome-mediated production of active interleukin (IL)-1. Even though progress in immunobiology and genetics has brought forth diagnostic tools and novel treatments that have been described in ...
Source: Pediatric Drugs - February 20, 2024 Category: Pediatrics Source Type: research
Correction: Enteral and Parenteral Treatment with Caffeine for Preterm Infants in the Delivery Room: A Randomised Trial
(Source: Pediatric Drugs)
Source: Pediatric Drugs - February 16, 2024 Category: Pediatrics Source Type: research
Existing and Emerging Targeted Therapies in Juvenile Psoriatic Arthritis: Challenges and Unmet Needs
AbstractJuvenile psoriatic arthritis (JPsA) is a heterogeneous type of non-systemic chronic inflammatory arthritis affecting children and young people. This review focuses on highlighting challenges in harmonising recommendations for the use of available therapies in JPsA, according to its distinct clinical phenotypes, and explores the similarities and differences between the disease classification and management across age. We further explore the emerging therapeutic landscape, summarising the recently completed clinical trials in JPsA, and ongoing studies in both JPsA and adults with psoriatic arthritis, highlighting unm...
Source: Pediatric Drugs - February 4, 2024 Category: Pediatrics Source Type: research
Improving Methylphenidate Titration in Children with Attention-Deficit/Hyperactivity Disorder (ADHD): A Randomized Controlled Trial Using Placebo-Controlled Titration Implemented in Clinical Practice
ConclusionsPCT can be used to improve detection of children who do not benefit from MPH, and may therefore potentially reduce overtreatment of ADHD with MPH. (Source: Pediatric Drugs)
Source: Pediatric Drugs - January 27, 2024 Category: Pediatrics Source Type: research
Real-World Data on the Use of Sirolimus in Asian Children with Vascular Malformations
ConclusionStarting dose of 1.5 –2 mg/m2 sirolimus is effective and safe in vascular malformation treatment. The best treatment regimen and discontinuation indications needed more investigation. Most should be done about targeted therapy to improve effectiveness and reduce side effects. (Source: Pediatric Drugs)
Source: Pediatric Drugs - January 27, 2024 Category: Pediatrics Source Type: research
Oral Ibuprofen for the Treatment of PDA in Preterm Neonates: Urgent Need for a Safer Alternative to Hyperosmolar Formulations
(Source: Pediatric Drugs)
Source: Pediatric Drugs - January 27, 2024 Category: Pediatrics Source Type: research
Infections in Children Aged 6 Months to 5 Years Treated with Dupilumab in a Placebo-Controlled Clinical Trial of Moderate-to-Severe Atopic Dermatitis
ConclusionsThese data suggest that dupilumab treatment in infants and children younger than 6 years with AD does not increase overall risk of infections and is associated with a reduced risk of bacterial and non-herpetic skin infections compared with placebo, resulting in a reduced need for anti-infective medication.Trial RegistrationThe trial was registered with ClinicalTrials.gov with ID number NCT03346434 on November 17, 2017.Infographic (Source: Pediatric Drugs)
Source: Pediatric Drugs - January 24, 2024 Category: Pediatrics Source Type: research
Use of Computerized Physician Order Entry with Clinical Decision Support to Prevent Dose Errors in Pediatric Medication Orders: A Systematic Review
ConclusionsThe CPOE –CDS systems have the potential to reduce pediatric dose errors. Most beneficial interventions seem to be system customization, implementing CDS alerts, and the use of dose range check. While human factors are still present within the medication use process, further studies and development activit ies are needed to optimize the usability of CPOE–CDS systems. (Source: Pediatric Drugs)
Source: Pediatric Drugs - January 19, 2024 Category: Pediatrics Source Type: research
